0 431

Cited 7 times in

Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study)

DC Field Value Language
dc.contributor.author손영호-
dc.contributor.author이양현-
dc.contributor.author이필휴-
dc.contributor.author정석종-
dc.contributor.author유한수-
dc.date.accessioned2021-09-29T00:38:55Z-
dc.date.available2021-09-29T00:38:55Z-
dc.date.issued2021-05-
dc.identifier.issn0009-9236-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/183970-
dc.description.abstractThe aim of this trial was to investigate the safety, tolerability, and capability of serum uric acid (UA) elevation of inosine 5'-monophosphate (IMP) in multiple system atrophy (MSA). The IMPROVE-MSA trial was a randomized, double-blind, placebo-controlled trial in patients with MSA with no history of hyperuricemia-related disorders. The participants were assigned to placebo (n = 25) or IMP (n = 30) in a 1 to 1 ratio, and then followed up for 24 weeks. The primary end points included safety, tolerability, and alteration of the serum UA level during the follow-up period. The secondary end points were changes in scores of the unified MSA rating scale (UMSARS) and the Mini-Mental Status Examination (MMSE) and Montreal Cognitive Assessment (MoCA). The total number of adverse events (AEs) and serious AEs was comparable between the active and placebo groups. Serum UA level (mg/dL) was significantly increased from baseline (active vs. placebo, 4.57 vs. 4.58; P = 0.98) to study end point (6.96 vs. 4.43; P < 0.001) in the active group compared with the placebo group (time × group interaction; P < 0.001). The change in UMSARS scores did not differ between the active and placebo groups. However, the active group showed better alterations in MoCA scores with nominal significance (P < 0.001) and tendency for better alterations in MMSE scores (P = 0.09) than the placebo group. Our data demonstrated that IMP treatment was generally safe and well-tolerated in patients with MSA. A further trial with a long-term follow-up is required to examine whether UA elevation will slow clinical progression in early MSA.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-
dc.relation.isPartOfCLINICAL PHARMACOLOGY & THERAPEUTICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleInosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학교실)-
dc.contributor.googleauthorJae Jung Lee-
dc.contributor.googleauthorJung Han Yoon-
dc.contributor.googleauthorSang Jin Kim-
dc.contributor.googleauthorHan Soo Yoo-
dc.contributor.googleauthorSeok Jong Chung-
dc.contributor.googleauthorYang Hyun Lee-
dc.contributor.googleauthorSuk Yun Kang-
dc.contributor.googleauthorHae-Won Shin-
dc.contributor.googleauthorSook Keun Song-
dc.contributor.googleauthorJin Yong Hong-
dc.contributor.googleauthorMunKyung Sunwoo-
dc.contributor.googleauthorJi Eun Lee-
dc.contributor.googleauthorJong Sam Baik-
dc.contributor.googleauthorYoung H Sohn-
dc.contributor.googleauthorPhil Hyu Lee-
dc.identifier.doi10.1002/cpt.2082-
dc.contributor.localIdA01982-
dc.contributor.localIdA05714-
dc.contributor.localIdA03270-
dc.contributor.localIdA04666-
dc.relation.journalcodeJ00608-
dc.identifier.eissn1532-6535-
dc.identifier.pmid33064299-
dc.identifier.urlhttps://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2082-
dc.contributor.alternativeNameSohn, Young Ho-
dc.contributor.affiliatedAuthor손영호-
dc.contributor.affiliatedAuthor이양현-
dc.contributor.affiliatedAuthor이필휴-
dc.contributor.affiliatedAuthor정석종-
dc.citation.volume109-
dc.citation.number5-
dc.citation.startPage1274-
dc.citation.endPage1281-
dc.identifier.bibliographicCitationCLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.109(5) : 1274-1281, 2021-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.